Sinusitis - Pipeline Insight, 2024

This “Sinusitis - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Sinusitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Sinusitis Understanding

Sinusitis: Overview

Sinusitis is present when the tissue lining the sinuses become swollen or inflamed. It occurs as the result of an inflammatory reaction or an infection from a virus, bacteria, or fungus. The sinuses are air-filled spaces in the skull. They are located behind the forehead, nasal bones, cheeks, and eyes. Healthy sinuses contain no bacteria or other germs. Most of the time, mucus is able to drain out and air is able to flow through the sinuses. There are different types of sinusitis, and they can last for various lengths of time. Acute sinusitis is temporary and can happen when a person has a cold or a seasonal allergy. Symptoms usually go away within 7-10 days but can last up to 4 weeks. Chronic sinusitis is when symptoms last more than 12 weeks or return three times within a year. Over 50% of people with moderate-to-severe asthma also have chronic sinusitis. Sinusitis is treated differently based on the cause. Most cases of acute sinusitis, about 98 percent, are caused by a virus, not bacteria, and should not be treated with antibiotics. Acute viral sinusitis may be treated using pain relievers such as acetaminophen or ibuprofen, steroid nasal sprays, or salt water irrigation in the nose. Chronic sinusitis is treated differently than acute sinusitis. Because chronic sinusitis is caused more by inflammation than infection, the treatments for chronic sinusitis aim to control the inflammation. Salt water nasal irrigation and/or nasal steroid sprays are the main treatments for the symptoms of chronic sinusitis. Antibiotics may sometimes be helpful but not always.

Sinusitis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sinusitis pipeline landscape is provided which includes the disease overview and Sinusitis treatment guidelines. The assessment part of the report embraces, in depth Sinusitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sinusitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Sinusitis.
• In the coming years, the Sinusitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics that are working to assess challenges and seek opportunities that could influence Sinusitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• A detailed portfolio of major pharma players who are involved in fueling the Sinusitis treatment market. Several potential therapies for Sinusitis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Sinusitis market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Sinusitis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Sinusitis Emerging Drugs Chapters

This segment of the Sinusitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Sinusitis Emerging Drugs

GLS-1200: GeneOne Life Science GLS-1200 nasal spray stimulates multiple bitter taste receptors (TAS2Rs) on ciliated nasal epithelial cells to produce nitric oxide as part of the innate immune system. Nitric oxide has generalized anti-microbial activity in the upper respiratory tract. Currently, it is in Phase II stage of clinical trial evaluation to treat chronicSinusitis.

LYR-210: Lyra Therapeutics Lyra’s lead product candidate, LYR-210, to treat chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses. LYR-210 is an anti-inflammatory implantable drug matrix based upon Lyra’s XTreo™ platform designed to elute mometasone furoate consistently and locally to the inflamed mucosal tissue of surgically-naïve CRS patients for up to six months from a single treatment. LYR-210 is being developed as an alternative to sinus surgery for CRS patients. Currently, it is in Phase III stage of clinical trial evaluation to treat chronic rhinosinusitis.

TRL 1068: TRELLIS BIOSCIENCETrellis Bioscience has used its Cell Spot Technology to identify a high-affinity and broad-spectrum native human antibody, TRL1068, which targets and disintegrates bacterial biofilm. Biofilm is a physiological factor promoting drug resistance in most clinically relevant multi-drug-resistant bacteria species, both gram positive and gram negative. Biofilm is also implicated as a factor promoting Alzheimer's pathogenesis. Currently, it is in Phase I stage of clinical trial evaluation to treat Chronic Rhinosinusitis with NasalPolyps.

Sinusitis: Therapeutic Assessment

This segment of the report provides insights about the different Sinusitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Sinusitis

There are approx. 15+ key companies which are developing the therapies for Sinusitis. The companies which have their Sinusitis drug candidates in the most advanced stage, i.e. phase III include, Lyra Therapeutics.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Sinusitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sinusitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sinusitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sinusitis drugs.

Sinusitis Report Insights

• Sinusitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Sinusitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Sinusitis drugs?
• How many Sinusitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sinusitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sinusitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Sinusitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• GeneOne Life Science
• Lyra Therapeutics
• TRELLIS BIOSCIENCE
• Sanotize Research and Development
• Sanofi
• OptiNose
• Biohaven Pharmaceuticals
• Keymed Biosciences Co.Ltd
• Suzhou Connect Biopharmaceuticals, Ltd.
• Genentech, Inc.
• Pfizer
• BEAM Alliance
• Insmed Incorporated
• Lanier Biotherapeutics
• GlycoMira
• IVIEW Therapeutics Inc.
• Nota Laboratories LLC
• Quorum Innovations

Key Products

• GLS-1200
• LYR-210
• TRL 1068
• Nitric Oxide
• Qi-301
• GM-1111
• Dupilumab
• IVIEW-1501/1502
• OPN-375
• VXD-005
• Brensocatib
• Rimegepant
• CM326
• CM310
• CBP-201
• Omalizumab
• PF-06817024
• LNR 125.38

This product will be delivered within 1-3 business days.